Adenovirus based HIV-1 vaccine candidates tested in efficacy trials elicit CD8 T-cells with limited breadth of HIV-1 inhibition.

COUNTER-compliant statistics provided by IRUS-UK.
Unless otherwise indicated, items in Spiral are protected by copyright and are licensed under a Creative Commons Attribution NonCommercial NoDerivatives License.